v3.25.2
Organization (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jul. 25, 2025
Jun. 03, 2025
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Cash and cash equivalents     $ 67,700,000   $ 67,700,000  
Net Income (Loss) Attributable to Parent         83,600,000 $ 15,800,000
Proceeds from issuance of common stock         $ 50,000,000 $ 5,537,975
Issuance of common stock     280,000 220,000    
Enlightened Isotopes [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Subsidiary ownership percentage     80.00%   80.00%  
PET Labs Pharmaceuticals [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Subsidiary ownership percentage     51.00%   51.00%  
Common Stocks            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Proceeds from issuance of common stock $ 56,400,000          
Issuance of common stock 7,500,000          
Shares issued price per share $ 8          
Common Stocks | Registered Direct Offering [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Proceeds from issuance of common stock   $ 46,800,000        
Issuance of common stock   7,518,797        
Shares issued price per share   $ 6.65